SCHEMBL20547008

SCHEMBL20547008

CCCCCc1c(C(N)=O)cccc1-c1ccc(C(N)=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.46
MKNK2 Q9HBH9 2/20 0.46
PPARG P37231 3/20 0.45
RARB P10826 8/20 0.42
LTB4R2 Q9NPC1 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
NR1I2 O75469 1/20 0.42
LMNA P02545 1/20 0.42
CHRM2 P08172 1/20 0.42
CYP3A4 P08684 1/20 0.42
ADRA2A P08913 1/20 0.42
OPRK1 P41145 1/20 0.42
HTR2B P41595 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TLR8 Q9NR97 1/20 0.41
BCAT2 O15382 1/20 0.41
APAF1 O14727 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370893 0.82 CYP3A4 (0.53) PPARGMEN1KMT2AMAPTNR1I2
SCHEMBL5482646 0.82 PPARG (0.45) PPARGLTB4R2MAPTBCAT2ALDH1A1
SCHEMBL27405674 0.81 LMNA (0.55) PPARGMEN1KMT2AMAPTNR1I2
SCHEMBL6535320 0.81 LMNA (0.55) PPARGMEN1KMT2AMAPTNR1I2
SCHEMBL28371050 0.81 LMNA (0.55) PPARGMEN1KMT2AMAPTNR1I2
SCHEMBL9051704 0.80 MAPT (0.46) PPARGMEN1KMT2AMAPTNR1I2
SCHEMBL1004987 0.79 PPARA (0.53) MKNK1MKNK2PPARGRARBMEN1
SCHEMBL5476512 0.79 BCAT2 (0.59) PPARGLTB4R2MEN1KMT2AMAPT
SCHEMBL9050807 0.78 MEN1 (0.42) PPARGLTB4R2MEN1KMT2AMAPT
SCHEMBL6013405 0.78 CXCR5 (0.51) PPARGRARBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550073-B2 Benzamide derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-02-04 US disclosed
US-20180312462-A1 BENZAMIDE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312462-A1 BENZAMIDE DERIVATIVE CYP3A5, ABCB1, CYP2D6 MKNK1 4865/4885MKNK2 4818/4885PPARG 917/4885
US-10550073-B2 Benzamide derivative CYP3A5, ABCB1, CYP2D6 MKNK1 4865/4885MKNK2 4818/4885PPARG 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.